Background: Beyond the hypometabolic signature, indexed by [18F]FDG‐PET imaging, seen in the brain of Alzheimer’s disease (AD) patients, a transient brain glucose hypermetabolism has been recently identified in the early stages of AD. The cellular source of this dual metabolic response remains controversial, with glial cells gaining a lot of attention. In light of this, whether glial and synaptic fluid biomarkers are associated with [18F]FDG‐PET signal in the early stages of AD remains debatable. Thus, we evaluated the association of astrocyte, microglial and synaptic fluid biomarkers with [18F]FDG‐PET signal in an AD rat model.Method: [18F]FDG‐PET imaging was conducted in ten‐month‐old (early amyloid stage) APP/PS1 (TgF344‐AD, n = 8‐17) and wild‐type (WT, n = 8‐15) rats. Glial (GFAP and sTREM2), synaptic (neurogranin), and amyloid biomarkers (Aß1‐40 and Aß1‐42) were quantified in the cerebrospinal fluid (CSF) and plasma through a multiplex immunoassay. T‐statistical maps of brain [18F]FDG‐PET and those fluid biomarkers were conducted at the voxel level using RMINC. Differences were considered statistically significant at p2).Result: A large hypermetabolic cluster was identified in ten‐month‐old TgF344‐AD (Fig. 1AB, local maxima, t(13) = 4.28). We found positive correlations between CSF TREM2 and brain [18F]FDG‐PET signal (Fig. 2AC, local maxima, t(13) = 4.12). In addition, we identified a positive correlation between plasma GFAP and brain [18F]FDG‐PET signal (Fig. 2BC, local maxima, t(13) = 10.62). Plasma TREM2, CSF GFAP, and plasma neurogranin did not associate with brain glucose metabolism.Conclusion: Our findings suggest that CSF TREM2 and plasma GFAP are associated with brain metabolism before amyloid load reaches a plateau. Stronger association of plasma GFAP, rather than CSF GFAP, with brain pathology corroborates cross‐sectional human studies. One could argue that [18F]FDG‐PET hypermetabolism identified is likely a response to astrocyte and microglial changes.